You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Of the 31 companies in the index, 11 firms saw their stock prices increase, while 20 saw their share prices decline.
Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 saw their share prices decline.
The firm's stock price has dropped since the announcement that the agency would need additional information and it has paused test shipments.
Growth was driven by demand in its life science segment, particularly for COVID-19-related products, while the diagnostics segment saw uneven improvement.
Not every company in the 360Dx Index had significant gains, but multiple companies saw their share prices double.
Of the 32 companies in the index, 21 firms saw their stock prices increase, while 11 firms' share prices decreased.
Quidel and Accelerate Diagnostics had the biggest declines in their share prices as the Index lagged behind the broader markets.
According to some analysts, the selloff in IVD company shares may be an overreaction, and SARS-CoV-2-related testing will be needed for some time in the future.
Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 firms' share prices decreased.
The investment bank projects medium-term revenue growth in the low teens, thanks to new test launches and expanded payor contracts for the company.